bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

1

Understanding the B and T cells epitopes of spike protein of severe respiratory syndrome

2

coronavirus-2: A computational way to predict the immunogens

3
4

Yoya Vashi†, Vipin Jagrit†, Sachin Kumar*

5
6

Viral Immunology Group, Department of Biosciences and Bioengineering, Indian Institute of

7

Technology Guwahati, Guwahati 781039 Assam India.

8
9

†Contributed equally

10
11

*Corresponding author Email: sachinku@iitg.ac.in (S Kumar)

12
13

Contact number: 91-3612582229

14
15
16
17
18
19
20
21
22
23

1

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

24

Abstract

25

The 2019 novel severe respiratory syndrome coronavirus-2 (SARS-CoV-2) outbreak

26

has caused a large number of deaths with thousands of confirmed cases worldwide. The present

27

study followed computational approaches to identify B- and T-cell epitopes for spike

28

glycoprotein of SARS-CoV-2 by its interactions with the human leukocyte antigen alleles. We

29

identified twenty-four peptide stretches on the SARS-CoV-2 spike protein that are well

30

conserved among the reported strains. The S protein structure further validated the presence of

31

predicted peptides on the surface. Out of which twenty are surface exposed and predicted to

32

have reasonable epitope binding efficiency. The work could be useful for understanding the

33

immunodominant regions in the surface protein of SARS-CoV-2 and could potentially help in

34

designing some peptide-based diagnostics.

35
36
37
38
39
40
41
42
43
44
45
46
47
48

Keywords: SARS-CoV-2; Spike protein; epitopes; diagnostics.
2

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

49
50

Introduction

51

Emerging severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a recent

52

pandemic and declared as a public health emergency by World Health Organization (WHO) 1.

53

The disease rapidly spread across the globe and caused havoc to humanity 2. By the end of

54

March, SARS-CoV-2 had spread to 200 countries and infected over 4,50,000 people 3. The

55

WHO is continuously monitoring and updating the health-related plans to curtail the disease

56

spread. The absence of specific treatment and vaccine worsen the situation and threat the world.

57

International Committee on Taxonomy of Viruses (ICTV), classified SARS-CoV-2

58

under family coronaviridae of order nidovirales. The genomic sequence of SARS-CoV-2

59

isolated from the bronchoalveolar lavage fluid of a patient from the Wuhan, China showed a

60

length of 29,903 nucleotides (GenBank accession number NC_045512) 4. The SARS-CoV-2

61

contains a positive single-stranded RNA with 5ˊ and 3ˊ UTR. The genome codes for ORF1a,

62

ORF1b, Spike (S), ORF3a, ORF3b, Envelope (E), Membrane (M), ORF6, ORF7a, ORF7b,

63

ORF8, ORF9b, ORF14, Nucleocapsid (N), and ORF10 from 5ˊ to 3ˊ 4,5.

64

The S glycoprotein forms homotrimers and represents a potential target for therapeutic

65

and vaccine design as it mediates viral entry into host cells 6,7. S glycoprotein comprises of two

66

functional subunits. Whereas the S1 subunit is responsible for binding to the host cell receptor,

67

the S2 subunit is responsible for the fusion of the viral with the cell membrane. Usually, in

68

CoVs, S is cleaved at the boundary between the S1 and S2 subunits, which remain non-

69

covalently bound in the prefusion conformation, to activate the protein for membrane fusion

70

via extensive irreversible conformational changes 8-10. Setting apart from other SARS-CoVs, it

71

is found that S glycoprotein of SARS-CoV-2 harbors a furin cleavage site at the boundary

72

between the S1/S2 subunits

73

converting enzyme 2 (ACE2) receptor-mediated entry into cells. It is found that the receptor-

11

. By now, it is evident that SARS-CoV-2 S uses angiotensin-

3

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

74

binding domains of S proteins of SARS-CoV-2 and SARS-CoV bind with similar affinities to

75

human ACE2 11,12.

76

As the situation worsens, there is a growing need for the development of suitable

77

therapeutics and alternate diagnostics against SARS-CoV-2 for effective disease management

78

strategies. Diagnostic assays based on peptides have become increasingly substantial and

79

indispensable for its advantages over conventional methods

80

locate appropriate epitopes within a particular protein antigen, which can elicit an immune

81

response that could be selected for the synthesis of the immunogenic peptide. Using

82

computational approach, S glycoprotein of SARS-CoV-2 was explored to identify various

83

immunodominant epitopes for the development of diagnostics. Besides, the results could also

84

help us to understand the SARS-CoV-2 surface protein response towards T and B cells.

13

. The present study aimed to

85
86

Materials & Methods

87

Collection of targeted protein sequence

88

We downloaded amino acid sequences (n=98) of S protein available at the time of study

89

on targeted SARS-CoV-2 from the National Centre for Biotechnological Information (NCBI)

90

database.

91

Identification of potential peptides

92

To identify an immunodominant region, it is of extreme importance to select the

93

conserved region within the S protein of SARS-CoV-2. All the sequences were compared

94

among themselves for variability using protein variability server by Shannon method

95

average solvent accessibility (ASA) profile was predicted for each sequence using SABLE

96

server 15. BepiPred 1.0 Linear Epitope Prediction module 16-18 incorporated in Immune Epitope

97

Database (IEDB)

98

sequence of the targeted protein was used as an input for all the default parameters.

19

14

. The

was used to predict potential epitopes within the S protein. The FASTA

4

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

99

Identification of B‐cell epitopes

100

We used two web-based tools for B-cell epitope prediction, viz., the IEDB, and

101

ABCpred server 20. S protein structure from protein data bank (PDB) (6VSB) 21 was analyzed

102

for linear and discontinuous B-cell epitopes using ElliPro module

103

default settings. Also, ABCpred server was used to detect B-cell epitopes using artificial neural

104

network (ann) method.

105

Identification of T‐cell epitopes

22

on IEDB server, with

106

T-cell epitopes having binding affinity towards MHC-I and MHC-II alleles were

107

selected to boost up both cytotoxic T‐cell and helper T‐cell mediated immune response. IEDB

108

server was used to predict the MHC-I and MHC-II binding epitopes for targeted protein. The

109

reference set of alleles was used for predicting the MHC-I and MHC-II T-cell epitopes. 23-27

110
111

Results and Discussion

112

In our study, we targeted the S glycoprotein of SARS-CoV-2 as it is present outside the

113

virus and interacts with the host receptor. At the time of the study, there were 98 sequences

114

available for the targeted protein of SARS-CoV-2. The S glycoprotein is 1273 amino acids

115

long sequence except for the virus isolated from Kerala (India), which is 1272 amino acids

116

long spike glycoprotein (GenBank accession number MT012098). Our interest here was to

117

determine conserved regions first and then determine surface-exposed regions, which are

118

potential epitopes to generate immune response. We found that sequences among all the S

119

proteins in the analysis are least variable and highly conserved as shown in Figure 1. Regions

120

having a high value of ASA are more surface exposed as compared to others. We identified a

121

total of 24 peptides of varying length, as shown in Table 1, which are selected based on high

122

ASA values. The potential epitope regions were predicted using the sequence of S protein of

123

SARS-CoV-2, which showed the least variability (GenBank accession number NC_045512).

5

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

124

The potential epitopes are represented by blue peaks, while green-colored slopes represent non-

125

epitopic regions (Figure 2).

126

The existence of B-cell linear and discontinuous (conformational) epitopes within the

127

identified segments could help us to identify the peptides, which can elicit immune response

128

28

129

19 of our selected peptides highlighted in red in Table 2. These identified B-cell linear epitopes

130

are placed based on their positional value, and scores. Epitopes with high scores have more

131

potential for antibody binding. Five of our selected peptides (peptide numbers 3, 5, 19, 23, and

132

24 in Table 1) were not considered as potential linear B-cell epitopes.

. We identified 18 linear epitopes, predicted by ElliPro (IEDB), which contains regions from

133

Using the same module, B-cell discontinuous epitopes were predicted, which gave 16

134

epitope regions that contained regions from 18 of our selected peptides highlighted in red

135

(Table 3). Six peptides (peptide numbers 3, 5, 14, 19, 23, and 24 in Table 1) were not predicted

136

as discontinuous B-cell epitopes. To further confirm, we used ABCpred server to detect B-cell

137

epitopes, with default threshold of 0.51. It identified various epitopes with different length and

138

scores; out of those, the regions which contained our selected peptides are highlighted in red

139

(Table 4). A high score represents a good binding affinity with epitopes, and most of our

140

peptides scored more than 0.7 and were predicted as linear B-cell epitopes.

141

We used the IEDB server to determine the binding affinity for human leucocyte antigen

142

(HLA) with our selected peptides from Table 1. As recommended by the IEDB server,

143

reference HLA allele sets were used for the prediction of MHC-I and MHC-II T-cell epitopes,

144

as they provide comprehensive coverage of the population. All the predictions were made using

145

IEDB recommended procedures. We observed good binding affinities for our selected peptides.

146

The list of binding affinities for MHC-I T-cell epitopes is given in Table 5, where low rank

147

represents high binding affinity. The epitopes with rank <1% for very high binding affinity

148

were selected. Regions from all of our selected peptides were found to be potential T-cell

6

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

149

epitope(s) with high binding affinity with HLA-A and HLA-B alleles, except one. Similarly,

150

the list of binding affinities for MHC-II T-cell epitopes are given in Table 6. Regions from our

151

selected peptides are highlighted in red. The results revealed that around half of our selected

152

peptides are potential T-cell epitope(s) with high binding affinity with HLA-DRB and HLA-

153

DP/DQ alleles.

154

Overall, it was found that the regions identified in Table 1 not only had good B-cell and

155

T-cell affinities, but the majority of them had overlaps with discontinuous epitopes also (Table

156

3). The peptide segments identified from the set of 98 sequences of the SARS-CoV-2 S

157

glycoprotein appear to hold reasonable potential to act as immunogens. Peptide-based

158

diagnostics and vaccines have been proposed against virus outbreaks earlier

159

availability of a 3D structure (6VSB) of the SARS-CoV-2 S glycoprotein provided an

160

opportunity to inspect the predicted peptides. Placement of the peptide segments identified by

161

ASA and conserved sequence analysis on the S glycoprotein showed that 20 regions that we

162

identified lie on the surface (Figure 3). In order to limit recognition and evade from immune

163

response of host, coronaviruses use conformational masking and glycan shielding 34,35. SARS-

164

CoV-2 S trimer also exists in multiple distinct conformational states, which is necessary for

165

receptor engagement leading to initiation of fusogenic conformational changes

166

considerable good number of peptides at the surface region of the S glycoprotein allows the

167

potential use of those peptide regions as immunogens.

29-33

. The

11

. A

168

The emergence of new viral diseases like SARS-CoV-2 represents a substantial global

169

disease burden. There is an urgent need for diagnostics, therapeutics, and vaccines against

170

newly emerged SARS-CoV-2. Facilitated by high mutation rates, traditional vaccines based on

171

antibody-mediated protection are often poor inducers of T cell responses and can have limited

172

success 36. In our study, we predicted both B-cell and T-cell epitopes for conferring immunity

173

in different ways. We speculate that the identified epitopes with considerably good epitope

7

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

174

binding efficiency have the potential to be an immunodominant peptide. Peptide-based

175

sensitive and rapid diagnostic kits are considered as a better alternative to the conventional

176

serological tests including whole antigenic protein

177

predicted peptide as an immunogen for the development of diagnostics against SARS-CoV-2.

13

. The study could help us to use the

178
179

Conclusion

180

In the present study, peptide segments were identified on S proteins for the development

181

of diagnostics against SARS-CoV-2. The recent availability of 3D data on 2019-CoV spike

182

glycoprotein has helped the search. SARS-CoV-2, being an RNA virus, has high mutations rate

183

and undergoing active recombination 37. Although the peptides identified are ideal candidates

184

as immunogens for peptide-based diagnostics development, more refinement and lab trials are

185

essential steps that are yet to be undertaken for early development of diagnostics before the

186

identified epitopes are rendered obsolete.

187
188

8

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

189

References:

190

1.

- 11 March 2020. 2020.

191
192

WHO. WHO Director-General's opening remarks at the media briefing on COVID-19

2.

Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus
Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020.

193
194

3.

WHO. Coronavirus disease 2019 (COVID-19) Situation Report - 66. 2020.

195

4.

Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory
disease in China. Nature. 2020;579(7798):265-269.

196
197

5.

in China, 2019. N Engl J Med. 2020;382(8):727-733.

198
199

6.

7.

Tortorici MA, Walls AC, Lang Y, et al. Structural basis for human coronavirus
attachment to sialic acid receptors. Nat Struct Mol Biol. 2019;26(6):481-489.

202
203

Li F. Structure, Function, and Evolution of Coronavirus Spike Proteins. Annu Rev Virol.
2016;3(1):237-261.

200
201

Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with Pneumonia

8.

Park JE, Li K, Barlan A, et al. Proteolytic processing of Middle East respiratory

204

syndrome coronavirus spikes expands virus tropism. Proc Natl Acad Sci U S A.

205

2016;113(43):12262-12267.

206

9.

Burkard C, Verheije MH, Wicht O, et al. Coronavirus cell entry occurs through the

207

endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog.

208

2014;10(11):e1004502.

209

10.

Walls AC, Tortorici MA, Snijder J, et al. Tectonic conformational changes of a

210

coronavirus spike glycoprotein promote membrane fusion. Proc Natl Acad Sci U S A.

211

2017;114(42):11157-11162.

212
213

11.

Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure,
Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020.

9

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

214

12.

for SARS-CoV-2 and other lineage B betacoronaviruses. Nat Microbiol. 2020.

215
216

Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage

13.

Mohanraj U, Chander S, Chavan YG. Peptide Based Viral Detection Systems for

217

Effective Diagnosis of Common Viral Infections in India. Curr Protein Pept Sci.

218

2017;18(9):939-945.

219

14.

Garcia-Boronat M, Diez-Rivero CM, Reinherz EL, Reche PA. PVS: a web server for

220

protein sequence variability analysis tuned to facilitate conserved epitope discovery.

221

Nucleic Acids Res. 2008;36(Web Server issue):W35-41.

222

15.

neural networks-based regression. Proteins. 2004;56(4):753-767.

223
224

16.

17.

18.

19.

20.

21.

237

Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in
the prefusion conformation. Science. 2020;367(6483):1260-1263.

235
236

Saha S, Raghava GP. Prediction of continuous B-cell epitopes in an antigen using
recurrent neural network. Proteins. 2006;65(1):40-48.

233
234

Vita R, Mahajan S, Overton JA, et al. The Immune Epitope Database (IEDB): 2018
update. Nucleic Acids Res. 2019;47(D1):D339-D343.

231
232

Haste Andersen P, Nielsen M, Lund O. Prediction of residues in discontinuous B-cell
epitopes using protein 3D structures. Protein Sci. 2006;15(11):2558-2567.

229
230

Ponomarenko JV, Bourne PE. Antibody-protein interactions: benchmark datasets and
prediction tools evaluation. BMC Struct Biol. 2007;7:64.

227
228

Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes.
Immunome Res. 2006;2:2.

225
226

Adamczak R, Porollo A, Meller J. Accurate prediction of solvent accessibility using

22.

Ponomarenko J, Bui HH, Li W, et al. ElliPro: a new structure-based tool for the
prediction of antibody epitopes. BMC Bioinformatics. 2008;9:514.

10

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

238

23.

Nielsen M, Lundegaard C, Worning P, et al. Reliable prediction of T-cell epitopes using

239

neural networks with novel sequence representations. Protein Sci. 2003;12(5):1007-

240

1017.

241

24.

Peters B, Sette A. Generating quantitative models describing the sequence specificity

242

of biological processes with the stabilized matrix method. BMC Bioinformatics.

243

2005;6:132.

244

25.

Karosiene E, Lundegaard C, Lund O, Nielsen M. NetMHCcons: a consensus method

245

for the major histocompatibility complex class I predictions. Immunogenetics.

246

2012;64(3):177-186.

247

26.

Nielsen M, Lundegaard C, Lund O. Prediction of MHC class II binding affinity using

248

SMM-align, a novel stabilization matrix alignment method. BMC Bioinformatics.

249

2007;8:238.

250

27.

Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA

251

ligand databases using DNA microarrays and virtual HLA class II matrices. Nat

252

Biotechnol. 1999;17(6):555-561.

253

28.

peptides in vaccine design. Nat Rev Drug Discov. 2007;6(5):404-414.

254
255

Purcell AW, McCluskey J, Rossjohn J. More than one reason to rethink the use of

29.

Oany AR, Emran AA, Jyoti TP. Design of an epitope-based peptide vaccine against

256

spike protein of human coronavirus: an in silico approach. Drug Des Devel Ther.

257

2014;8:1139-1149.

258

30.

a Zika virus vaccine. Comput Biol Chem. 2017;68:143-152.

259
260

Dey S, Nandy A, Basak SC, Nandy P, Das S. A Bioinformatics approach to designing

31.

Ichihashi T, Yoshida R, Sugimoto C, Takada A, Kajino K. Cross-protective peptide

261

vaccine against influenza A viruses developed in HLA-A*2402 human immunity

262

model. PLoS One. 2011;6(9):e24626.

11

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

263

32.

Navalkar KA, Johnston SA, Stafford P. Peptide based diagnostics: are random-

264

sequence peptides more useful than tiling proteome sequences? J Immunol Methods.

265

2015;417:10-21.

266

33.

E virus. Virol J. 2009;6:186.

267
268

34.

Walls AC, Xiong X, Park YJ, et al. Unexpected Receptor Functional Mimicry
Elucidates Activation of Coronavirus Fusion. Cell. 2019;176(5):1026-1039 e1015.

269
270

Zhao K, Liu Q, Yu R, et al. Screening of specific diagnostic peptides of swine hepatitis

35.

Xiong X, Tortorici MA, Snijder J, et al. Glycan Shield and Fusion Activation of a

271

Deltacoronavirus Spike Glycoprotein Fine-Tuned for Enteric Infections. J Virol.

272

2018;92(4).

273

36.

to viral infections - opportunities for Peptide vaccination. Front Immunol. 2014;5:171.

274
275
276

Rosendahl Huber S, van Beek J, de Jonge J, Luytjes W, van Baarle D. T cell responses

37.

Yi H. 2019 novel coronavirus is undergoing active recombination. Clin Infect Dis.
2020.

277
278
279
280
281
282
283
284
285
286
287

12

bioRxiv preprint doi: https://doi.org/10.1101/2020.04.08.013516; this version posted April 10, 2020. The copyright holder for this preprint (which
was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission.

288

Figure legends

289

Figure 1. Profiles of average solvent accessibility (blue) in % and amino acid sequence

290

variability (green) in numbers of the 98 SARS-CoV-2 protein plotted against amino acid

291

numbers.

292
293

Figure 2. Graphical representation of B-cell linear epitopes of spike protein of SARS-CoV-2.

294

B-cell linear epitopes predicted using BepiPred 1.0 module incorporated in IEDB server using

295

default threshold value (0.35).

296
297
298

Figure 3. Our selected peptides are highlighted on spike protein of SARS-CoV-2 protein
structure downloaded from PDB (ID: 6VSB).

299

13

1
32
63
94
125
156
187
218
249
280
311
342
373
404
435
466
497
528
559
590
621
652
683
714
745
776
807
838
869
900
931
962
993
1024
1055
1086
1117
1148
1179
1210
1241
1272

Figure 1.

ASA & sequence variability profile for spike protein of SARS-CoV-2

40
Variability

Amino acid numbers

ASA

35

30

25

20

15

10

5

0

1
35
69
103
137
171
205
239
273
307
341
375
409
443
477
511
545
579
613
647
681
715
749
783
817
851
885
919
953
987
1021
1055
1089
1123
1157
1191
1225
1259

Score

Figure 2.

3

2

Threshold

1

0

-1

-2

-3

-4

Position

Figure 3.

Table 1. Conserved region with good average solvent accessibility selected for further analysis.
Sl. No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Start
21
69
144
178
249
278
314
407
437
461
493
521
567
597
625
654
673
700
768
788
805
1134
1153
1255

End
38
81
155
191
261
287
325
428
450
485
506
533
581
607
648
661
691
713
780
799
816
1150
1171
1267

Length
18
13
12
14
13
10
12
22
14
25
14
13
15
11
24
8
19
16
13
14
12
17
19
13

Peptide
RTQLPPAYTNSFTRGVYY
HVSGTNGTKRFDN
YYHKNNKSWMES
DLEGKQGNFKNLRE
LTPGDSSSGWTAG
KYNENGTITD
QTSNFRVQPTES
VRQIAPGQTGKIADYNYKLPDD
NSNNLDSKVGGNYN
LKPFERDISTEIYQAGSTPCNGVEG
QSYGFQPTNGVGYQ
PATVCGPKKSTNL
RDIADTTDAVRDPQT
VITPGTNTSNQ
HADQLTPTWRVYSTGSNVFQTRAG
EHVNNSYE
SYQTQTNSPRRARSVASQS
GAENSVAYSNNSIA
TGIAVEQDKNTQE
IYKTPPIKDFGG
ILPDPSKPSKRS
NNTVYDPLQPELDSFKE
DKYFKNHTSPDVDLGDISG
KFDEDDSEPVLKG

Table 2. IEDB ElliPro predicted linear epitopes for spike protein of SARS-CoV-2. Sequences that match our selected peptides are
marked in red.
Sl.
No.
1

Start

End

27

37

2

56

196

3
4

280
322

286
375

5

393

515

6
7
8
9
10
11
12
13
14
15
16
17

464
465
520
577
603
616
652
687
700
789
789
807

511
509
537
585
608
643
661
691
719
805
815
815

18

1069

1146

Peptide
AYTNSFTRGVY
LPFFSNVTWFHFDNPVLPFNDGVYFASTNIIRGWIFGTTLDSKTQSLLIVNNAT
NVVIKVCEFQFCNDPFLGEFRVYSSANNCTFEYVSQPFLKNLREFVFKN
NENGTIT
PTESIVRFPNITNLCPFGEVFNATRFASVYAWNRKRISNCVADYSVLYNSASFS
TNVYADSFVIRGDEVRQIAPGQTGKIADYNYKLPDDFTGCVIAWNSNNLDSY
NYLYRPLQSYGFQPTVGYQPYRVVVLSF
FERDISTEIYNCYFPLQSYGFQPTVGYQPYRVV
ERDISTENCYFPLQSYGFQVGYQPYR
APATVCGPKKSTNLVKNK
RDPQTLEIL
NTSNQV
NCTEVTGSNVF
GAEHVNNSYE
VASQS
GAENSVAYSNNSIAIPTNFT
YKTPPIKDFGGFNFSQI
YKTPPIKDFGGFNFSQILPDPSKR
PDPSKR
PAQEKNFTTAPAICHDGKAHFPREGVFVSNGTHWFVTQRNFYEPQIITTDNTF
VSGNCDVVIGIVNNTVYDPLQPELD

No. of
residues
11

Score
0.701

103

0.851

7
54

0.521
0.646

80

0.842

33
26
18
9
6
11
10
5
20
17
24
6

0.707
0.663
0.617
0.665
0.522
0.578
0.594
0.612
0.659
0.621
0.609
0.558

78

0.832

Table 3. IEDB ElliPro predicted discontinuous epitopes for spike protein of SARS-CoV-2. Sequences that match our selected peptides
are marked in red.
Sl. No.
1

Residues
A:D1139, A:P1140, A:L1141, A:Q1142, A:P1143, A:E1144, A:L1145, A:D1146

No. of
residues

Score

8

0.962

2

A:T323, A:E324, A:S325, A:I326, A:V327, A:R328, A:L335, A:C336, A:P337, A:F338, A:G339,
A:E340, A:V341, A:F342, A:N343, A:A344, A:T345, A:R346, A:F347, A:A348, A:S349, A:V350,
A:Y351, A:A352, A:W353, A:N354, A:R355, A:K356, A:R357, A:I358, A:S359, A:N360, A:C361,
A:V362, A:A363, A:D364, A:Y365, A:S366, A:V367, A:L368, A:Y369, A:N370, A:S371, A:A372,
A:S373, A:F374, A:S375, A:T376, A:F377, A:K378, A:C379, A:Y380, A:V382, A:S383, A:P384,
A:T385, A:L387, A:N388, A:L390, A:T393, A:N394, A:V395, A:Y396, A:A397, A:D398, A:S399,
A:F400, A:V401, A:I402, A:R403, A:G404, A:D405, A:E406, A:V407, A:R408, A:Q409, A:I410,
A:A411, A:P412, A:G413, A:Q414, A:T415, A:G416, A:K417, A:I418, A:A419, A:D420, A:Y421,
A:N422, A:Y423, A:K424, A:L425, A:P426, A:D427, A:D428, A:F429, A:T430, A:G431, A:C432,
A:V433, A:I434, A:A435, A:W436, A:N437, A:S438, A:N439, A:N440, A:L441, A:D442, A:S443,
A:Y449, A:N450, A:Y451, A:L452, A:Y453, A:R454, A:P491, A:L492, A:Q493, A:S494, A:Y495,
A:G496, A:F497, A:Q498, A:P499, A:T500, A:V503, A:G504, A:Y505, A:Q506, A:P507, A:Y508,
A:R509, A:V510, A:V511, A:V512, A:L513, A:S514, A:F515, A:P521, A:A522, A:T523, A:V524,
A:G526, A:P527, A:K528, A:K529, A:S530, A:T531, A:N532, A:L533, A:V534, A:K535, A:N536,
A:K537, A:E554, A:S555, A:N556, A:K557, A:F559, A:L560, A:P561, A:F562, A:Q563, A:Q564,
A:R577, A:D578, A:P579, A:Q580, A:T581, A:L582, A:E583, A:I584, B:A27, B:Y28, B:T29,
B:N30, B:S31, B:F32, B:T33, B:R34, B:G35, B:V36, B:Y37, B:Y38, B:K41, B:L56, B:P57, B:F58,
B:F59, B:S60, B:N61, B:V62, B:T63, B:W64, B:F65, B:H66, B:N81, B:P82, B:V83, B:L84, B:P85,
B:F86, B:N87, B:D88, B:G89, B:V90, B:Y91, B:F92, B:A93, B:S94, B:T95, B:E96, B:K97, B:S98,
B:N99, B:I100, B:I101, B:R102, B:G103, B:W104, B:I105, B:F106, B:G107, B:T108, B:T109,
B:L110, B:D111, B:S112, B:K113, B:T114, B:Q115, B:S116, B:L117, B:L118, B:I119, B:V120,
B:N121, B:N122, B:A123, B:T124, B:N125, B:V126, B:V127, B:I128, B:K129, B:V130, B:C131,
B:E132, B:F133, B:Q134, B:F135, B:C136, B:N137, B:D138, B:P139, B:F140, B:L141, B:S155,
B:E156, B:F157, B:V159, B:Y160, B:S161, B:S162, B:A163, B:N164, B:N165, B:C166, B:T167,
B:F168, B:E169, B:Y170, B:V171, B:S172, B:Q173, B:P174, B:F175, B:L176, B:K187, B:N188,
B:L189, B:R190, B:E191, B:F192, B:V193, B:F194, B:K195, B:G199, B:F201, B:I203, B:Y204,
B:S205, B:K206, B:H207, B:T208, B:P209, B:P217, B:Q218, B:G219, B:F220, B:S221, B:A222,
B:L223, B:E224, B:P225, B:L226, B:V227, B:D228, B:L229, B:P230, B:I231, B:G232, B:I233,
B:N234, B:I235, B:T236, B:R237, B:F238, B:Q239, B:T240, B:L241, B:L242, B:A263, B:A264,
B:Y265, B:Y266, B:V267, B:G268, B:Y269, B:L270

331

0.774

3

B:P322, B:T323, B:E324, B:S325, B:I326, B:V327, B:R328, B:F329, B:P330, B:N331, B:I332,
B:T333, B:N334, B:L335, B:C336, B:P337, B:F338, B:G339, B:E340, B:V341, B:F342, B:N343,
B:A344, B:T345, B:R346, B:F347, B:A348, B:S349, B:V350, B:Y351, B:A352, B:W353, B:N354,
B:R355, B:K356, B:R357, B:I358, B:S359, B:N360, B:C361, B:V362, B:A363, B:D364, B:S366,
B:V367, B:L368, B:N370, B:S371, B:A372, B:S373, B:F374, B:C391, B:F392, B:T393, B:A397,
B:D398, B:S399, B:F400, B:V401, B:I402, B:R403, B:G404, B:Y421, B:N422, B:Y423, B:W436,
B:N437, B:S438, B:N439, B:N440, B:L441, B:D442, B:S443, B:Y449, B:N450, B:Y451, B:L452,
B:Y453, B:R454, B:N460, B:L461, B:K462, B:E465, B:R466, B:D467, B:I468, B:S469, B:T470,
B:E471, B:I472, B:Y473, B:N487, B:C488, B:Y489, B:F490, B:P491, B:L492, B:Q493, B:S494,
B:Y495, B:G496, B:F497, B:Q498, B:P499, B:T500, B:V503, B:G504, B:Y505, B:Q506, B:P507,
B:Y508, B:R509, B:V510, B:V511, B:A520, B:P521, B:A522, B:T523, B:V524, B:C525, B:G526,
B:P527, B:K528, B:K529, B:S530, B:T531, B:N532, B:L533, B:V534, B:K535, B:N536, B:K537,
B:N544, B:T553, B:E554, B:S555, B:N556, B:K557, B:F559, B:L560, B:P561, B:F562, B:Q563,
B:Q564, B:R577, B:D578, B:P579, B:Q580, B:T581, B:L582, B:E583, B:I584, B:L585, C:A27,
C:Y28, C:T29, C:N30, C:S31, C:F32, C:T33, C:R34, C:G35, C:V36, C:Y37, C:K41, C:F43, C:L56,
C:P57, C:F58, C:F59, C:S60, C:N61, C:V62, C:T63, C:W64, C:F65, C:H66, C:D80, C:N81, C:P82,
C:V83, C:L84, C:P85, C:F86, C:N87, C:D88, C:G89, C:V90, C:Y91, C:F92, C:A93, C:S94, C:T95,
C:N99, C:I100, C:I101, C:R102, C:G103, C:W104, C:I105, C:F106, C:G107, C:T108, C:T109,
C:L110, C:D111, C:S112, C:K113, C:T114, C:Q115, C:S116, C:L117, C:L118, C:I119, C:V120,
C:N121, C:N122, C:A123, C:T124, C:N125, C:V126, C:V127, C:I128, C:K129, C:V130, C:C131,
C:E132, C:F133, C:Q134, C:F135, C:C136, C:N137, C:D138, C:P139, C:F140, C:F157, C:R158,
C:V159, C:Y160, C:S161, C:S162, C:A163, C:N164, C:N165, C:C166, C:T167, C:F168, C:E169,
C:Y170, C:V171, C:S172, C:Q173, C:P174, C:F175, C:L176, C:K187, C:N188, C:L189, C:R190,
C:E191, C:F192, C:V193, C:F194, C:K195, C:N196, C:D198, C:G199, C:F201, C:K202, C:I203,
C:Y204, C:S205, C:K206, C:H207, C:T208, C:P209, C:I210, C:N211, C:L212, C:V213, C:R214,
C:D215, C:L216, C:P217, C:Q218, C:G219, C:F220, C:S221, C:A222, C:L223, C:E224, C:P225,
C:L226, C:V227, C:D228, C:L229, C:P230, C:I231, C:G232, C:I233, C:N234, C:I235, C:T236,
C:R237, C:F238, C:Q239, C:T240, C:L241, C:L242, C:A243, C:L244, C:H245, C:G261, C:A262,
C:A263, C:A264, C:Y265, C:Y266, C:V267, C:G268, C:Y269, C:L270, C:T286

323

0.737

4

A:A701, A:E702, A:N703, A:S704, A:V705, A:A706, A:Y707, A:S708, A:N709, A:N710, A:S711,
A:I712, A:A713, A:I714, A:P715, A:T716, A:N717, A:F718, A:T719, A:Q787, A:Y789, A:K790,
A:T791, A:P792, A:P793, A:I794, A:K795, A:D796, A:F797, A:G798, A:G799, A:F800, A:N801,
A:F802, A:S803, A:Q804, A:I805, A:L806, A:T883, A:G891, A:A892, A:A893, A:L894, A:Q895,
A:I896, A:P897, A:F898, A:A899, A:M900, A:A903, A:F906, A:N907, A:G910, A:V911, A:T912,
A:Q913, A:N914, A:V915, A:L916, A:Y917, A:E918, A:N919, A:Q920, A:L922, A:I923, A:A924,
A:N925, A:Q926, A:F927, A:N928, A:S929, A:G932, A:D936, A:P1069, A:A1070, A:Q1071,
A:E1072, A:K1073, A:N1074, A:F1075, A:T1076, A:T1077, A:A1078, A:P1079, A:A1080,
A:I1081, A:C1082, A:H1083, A:D1084, A:G1085, A:K1086, A:A1087, A:H1088, A:F1089,
A:P1090, A:R1091, A:E1092, A:G1093, A:V1094, A:F1095, A:V1096, A:S1097, A:N1098,
A:G1099, A:T1100, A:H1101, A:W1102, A:F1103, A:V1104, A:T1105, A:Q1106, A:R1107,
A:N1108, A:F1109, A:Y1110, A:E1111, A:P1112, A:Q1113, A:I1114, A:I1115, A:T1116, A:T1117,
A:D1118, A:N1119, A:T1120, A:F1121, A:V1122, A:S1123, A:G1124, A:N1125, A:C1126,
A:D1127, A:V1128, A:V1129, A:I1130, A:G1131, A:I1132, A:V1133, A:N1134, A:N1135,
A:T1136, A:V1137, A:Y1138, B:G700, B:A701, B:E702, B:N703, B:S704, B:V705, B:A706,
B:Y707, B:S708, B:N709, B:N710, B:S711, B:I712, B:A713, B:I714, B:P715, B:T716, B:N717,
B:F718, B:T719, B:Q787, B:I788, B:Y789, B:K790, B:T791, B:P792, B:P793, B:I794, B:K795,
B:D796, B:F797, B:G798, B:G799, B:F800, B:N801, B:F802, B:S803, B:Q804, B:I805, B:L806,
B:T883, B:G891, B:A892, B:A893, B:L894, B:Q895, B:I896, B:P897, B:F898, B:A899, B:M900,
B:M902, B:A903, B:F906, B:N907, B:G910, B:V911, B:T912, B:Q913, B:N914, B:V915, B:L916,
B:Y917, B:E918, B:N919, B:Q920, B:K921, B:L922, B:I923, B:A924, B:N925, B:Q926, B:F927,
B:N928, B:S929, B:P1069, B:A1070, B:Q1071, B:E1072, B:K1073, B:N1074, B:F1075, B:T1076,
B:T1077, B:A1078, B:P1079, B:A1080, B:I1081, B:C1082, B:H1083, B:D1084, B:G1085, B:K1086,
B:A1087, B:H1088, B:F1089, B:P1090, B:R1091, B:E1092, B:G1093, B:V1094, B:F1095, B:V1096,
B:S1097, B:N1098, B:G1099, B:T1100, B:H1101, B:W1102, B:F1103, B:V1104, B:T1105,
B:Q1106, B:R1107, B:N1108, B:F1109, B:Y1110, B:E1111, B:P1112, B:Q1113, B:I1114, B:I1115,
B:T1116, B:T1117, B:D1118, B:N1119, B:T1120, B:F1121, B:V1122, B:S1123, B:G1124, B:N1125,
B:C1126, B:D1127, B:V1128, B:V1129, B:I1130, B:G1131, B:I1132, B:V1133, B:N1134, B:N1135,
B:T1136, B:V1137, B:Y1138, B:D1139, B:P1140, B:L1141, B:Q1142, B:P1143, B:E1144, B:L1145,
B:D1146, C:A701, C:E702, C:N703, C:S704, C:V705, C:A706, C:Y707, C:S708, C:N709, C:N710,
C:S711, C:I712, C:A713, C:I714, C:P715, C:T716, C:N717, C:F718, C:T719, C:Q787, C:I788,
C:Y789, C:K790, C:T791, C:P792, C:P793, C:I794, C:K795, C:D796, C:F797, C:G798, C:G799,
C:F800, C:N801, C:F802, C:S803, C:Q804, C:I805, C:L806, C:P807, C:D808, C:P809, C:S810,

452

0.724

C:K811, C:R815, C:F817, C:T883, C:G891, C:A892, C:A893, C:L894, C:Q895, C:I896, C:P897,
C:F898, C:A899, C:M900, C:A903, C:F906, C:N907, C:G910, C:V911, C:T912, C:Q913, C:N914,
C:V915, C:L916, C:Y917, C:E918, C:N919, C:Q920, C:K921, C:L922, C:I923, C:A924, C:N925,
C:Q926, C:N928, C:S929, C:A1070, C:Q1071, C:E1072, C:K1073, C:N1074, C:F1075, C:T1076,
C:T1077, C:A1078, C:P1079, C:A1080, C:I1081, C:C1082, C:H1083, C:D1084, C:G1085, C:K1086,
C:A1087, C:H1088, C:F1089, C:P1090, C:R1091, C:E1092, C:G1093, C:V1094, C:F1095, C:V1096,
C:S1097, C:N1098, C:G1099, C:T1100, C:H1101, C:W1102, C:F1103, C:V1104, C:T1105,
C:Q1106, C:R1107, C:N1108, C:F1109, C:Y1110, C:E1111, C:P1112, C:Q1113, C:I1114, C:I1115,
C:T1116, C:T1117, C:D1118, C:N1119, C:T1120, C:F1121, C:V1122, C:S1123, C:G1124, C:N1125,
C:C1126, C:D1127, C:V1128, C:V1129, C:I1130, C:G1131, C:I1132, C:V1133, C:N1134, C:N1135,
C:T1136, C:V1137, C:Y1138, C:D1139, C:P1140, C:L1141, C:Q1142, C:P1143, C:E1144, C:L1145,
C:D1146

5

A:A27, A:Y28, A:T29, A:N30, A:S31, A:F32, A:T33, A:R34, A:G35, A:V36, A:Y37, A:Y38,
A:K41, A:F43, A:L56, A:P57, A:F58, A:F59, A:S60, A:N61, A:V62, A:T63, A:W64, A:F65, A:F79,
A:D80, A:N81, A:P82, A:V83, A:L84, A:P85, A:F86, A:N87, A:D88, A:G89, A:V90, A:Y91, A:F92,
A:A93, A:S94, A:T95, A:I100, A:I101, A:R102, A:G103, A:W104, A:I105, A:F106, A:G107,
A:T108, A:T109, A:L110, A:D111, A:S112, A:K113, A:T114, A:Q115, A:S116, A:L117, A:L118,
A:I119, A:V120, A:N121, A:N122, A:A123, A:T124, A:N125, A:V126, A:V127, A:I128, A:K129,
A:V130, A:C131, A:E132, A:F133, A:Q134, A:F135, A:C136, A:N137, A:D138, A:P139, A:F140,
A:L141, A:G142, A:E156, A:F157, A:R158, A:V159, A:Y160, A:S161, A:S162, A:A163, A:N164,
A:N165, A:C166, A:T167, A:F168, A:E169, A:Y170, A:V171, A:S172, A:Q173, A:P174, A:F175,
A:L176, A:K187, A:N188, A:L189, A:R190, A:E191, A:F192, A:V193, A:F194, A:N196, A:G199,
A:F201, A:K202, A:I203, A:Y204, A:S205, A:K206, A:H207, A:T208, A:P209, A:I210, A:N211,
A:L212, A:V213, A:R214, A:D215, A:L216, A:P217, A:Q218, A:G219, A:F220, A:S221, A:A222,
A:L223, A:E224, A:P225, A:L226, A:V227, A:D228, A:L229, A:P230, A:I231, A:G232, A:I233,
A:N234, A:I235, A:T236, A:R237, A:F238, A:Q239, A:T240, A:L241, A:L242, A:A243, A:L244,
A:H245, A:R246, A:G261, A:A262, A:A263, A:A264, A:Y265, A:Y266, A:V267, A:G268, A:Y269,
A:L270, A:R273, A:N280, A:E281, A:N282, A:G283, A:T284, A:T286, C:P322, C:T323, C:E324,
C:S325, C:I326, C:V327, C:R328, C:F329, C:P330, C:N331, C:I332, C:T333, C:N334, C:L335,
C:C336, C:P337, C:F338, C:G339, C:E340, C:V341, C:F342, C:N343, C:A344, C:T345, C:R346,
C:F347, C:A348, C:S349, C:V350, C:Y351, C:A352, C:N354, C:R357, C:I358, C:S359, C:N360,
C:C361, C:V362, C:A363, C:D364, C:S366, C:V367, C:N370, C:S371, C:A372, C:S373, C:F374,
C:T393, C:S399, C:V401, C:G404, C:W436, C:N437, C:S438, C:N439, C:N440, C:L441, C:D442,
C:S443, C:Y449, C:N450, C:Y451, C:L452, C:Y453, C:R454, C:E465, C:R466, C:D467, C:I468,
C:S469, C:T470, C:E471, C:F490, C:P491, C:L492, C:Q493, C:S494, C:Y495, C:G496, C:F497,
C:Q498, C:V503, C:G504, C:Y505, C:Q506, C:P507, C:Y508, C:R509, C:A522, C:T523, C:G526,
C:P527, C:K528, C:K529, C:S530, C:T531, C:N532, C:L533, C:V534, C:K535, C:N536, C:K537,
C:T553, C:E554, C:S555, C:N556, C:K557, C:K558, C:F559, C:L560, C:P561, C:F562, C:Q563,
C:Q564, C:R577, C:D578, C:P579, C:Q580, C:T581, C:L582, C:E583, C:I584, C:L585

6

301

0.723

A:V687, A:A688, A:S689, A:Q690, A:S691

5

0.612

7

B:T638, B:G639, B:S640, B:N641, B:V642, B:F643, B:G652, B:A653, B:E654, B:H655, B:V656,
B:N657, B:N658, B:S659, B:Y660, B:A672, B:V687, B:A688, B:S689, B:Q690, B:S691, B:I692,
B:I693, B:A694, B:S698

25

0.607

8

A:P807, A:D808, A:P809, A:S810, A:K811

5

0.596

9
10
11
12
13
14
15
16

C:N641, C:V642, C:G652, C:A653, C:E654, C:H655, C:V656, C:N657, C:N658, C:S659, C:Y660,
C:V687, C:A688, C:S689, C:Q690, C:S691, C:I693
A:H655, A:V656, A:N657, A:N658, A:S659, A:Y660
A:S640, A:N641, A:V642, A:G652, A:A653
B:P807, B:D808, B:P809, B:S810, B:K811, B:R815
B:G932, B:K933, B:D936
B:N280, B:E281, B:N282, B:G283, B:T284, B:T286
B:K558, C:S45, C:N280, C:E281, C:N282, C:G283, C:T284
C:G932, C:Q935, C:D936

17

0.592

6
5
6
3
6
7
3

0.57
0.551
0.549
0.532
0.523
0.519
0.519

Table 4. ABCpred determination of B-cell binding affinities. Note that high score indicates good binding affinity.
Sl. No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24

Sequence
PPAYTNSFTRGVYY
IHVSGTNGTKRFDNPVLPFN
VYYHKNNKSWMESEFRVYSS
DLEGKQGNFKNLREFVFKNI
YLTPGDSSSGWT
LLKYNENGTITDAVDCALDP
IYQTSNFRVQPTES
RQIAPGQTGKIADYNYKLPD
WNSNNLDSKVGGNYNYLY
SNLKPFERDISTEIYQAGST
LQSYGFQPTNGVGYQP
HAPATVCGPKKSTN
QQFGRDIADTTDAVRDPQTL
VITPGTNTSNQVAV
AIHADQLTPTWRVYSTGS
IGAEHVNNSYECDIPIGAGI
YQTQTNSPRRARSVASQS
GAENSVAYSNNSIAIPTN
AVEQDKNTQEVFAQ
IYKTPPIKDFGGFN
ILPDPSKPSKRSFIEDLL
VIGIVNNTVYDPLQPE
DKYFKNHTSPDVDLGD
CSCGSCCKFDEDDSEPVLKG

Start
25
68
143
178
248
276
312
408
436
459
492
519
563
597
623
651
674
700
771
788
805
1129
1153
1248

Score
0.91
0.89
0.9
0.82
0.7
0.76
0.68
0.75
0.67
0.82
0.9
0.72
0.82
0.77
0.67
0.9
0.82
0.63
0.89
0.77
0.63
0.83
0.69
0.73

Table 5. IEDB prediction of binding affinity with MHC-I alleles, only our selected peptides with percentile rank less than 1.00 are
shown here. The binding affinity is considered higher for low percentile rank. Sequences that match our selected peptides are marked
in red.

1
2
3
4
5
6
7
8
9
10

HLA-A*01:01
HLA-A*30:01
HLA-A*31:01
HLA-A*68:01
HLA-B*15:01
HLA-A*30:02
HLA-B*07:02
HLA-B*35:01
HLA-A*01:01
HLA-A*01:01

17
19
21
21
23
24
24
24
25
27

28
27
34
34
32
37
32
32
38
38

NLTTRTQLPPAY
TTRTQLPPA
RTQLPPAYTNSFTR
RTQLPPAYTNSFTR
QLPPAYTNSF
LPPAYTNSFTRGVY
LPPAYTNSF
LPPAYTNSF
PPAYTNSFTRGVYY
AYTNSFTRGVYY

ann
Consensus
ann
ann
Consensus
ann
Consensus
Consensus
ann
ann

Percentile
Rank
0.21
0.2
0.47
0.82
0.43
0.76
0.6
0.6
0.04
0.04

11

HLA-A*68:01

69

78

HVSGTNGTKR

Consensus

0.41

12
13
14
15
16

HLA-A*03:01
HLA-A*11:01
HLA-A*23:01
HLA-A*24:02
HLA-A*33:01

142
142
144
144
145

150
150
157
157
158

GVYYHKNNK
GVYYHKNNK
YYHKNNKSWMESEF
YYHKNNKSWMESEF
YHKNNKSWMESEFR

Consensus
Consensus
ann
ann
ann

0.2
0.43
0.62
0.38
0.56

17
18
19
20
21

HLA-A*11:01
HLA-A*31:01
HLA-A*23:01
HLA-A*33:01
HLA-B*44:03

182
182
185
185
187

195
190
194
195
200

KQGNFKNLREFVFK
KQGNFKNLR
NFKNLREFVF
NFKNLREFVFK
KNLREFVFKNIDGY

ann
Consensus
Consensus
ann
ann

0.99
0.19
0.71
0.67
0.64

Sl. No.

Allele

Start

End

Peptide

Method

22
23
24
25
26
27
28
29

HLA-B*57:01
HLA-B*58:01
HLA-B*53:01
HLA-A*30:02
HLA-A*26:01
HLA-A*01:01
HLA-A*68:02
HLA-A*30:02

246
246
250
252
253
254
254
255

259
259
258
265
266
266
267
266

RSYLTPGDSSSGWT
RSYLTPGDSSSGWT
TPGDSSSGW
GDSSSGWTAGAAAY
DSSSGWTAGAAAYY
SSSGWTAGAAAYY
SSSGWTAGAAAYYV
SSGWTAGAAAYY

ann
ann
Consensus
ann
ann
ann
ann
ann

0.38
0.47
0.2
0.28
0.11
0.34
0.39
0.09

30

HLA-A*68:02

281

289

ENGTITDAV

Consensus

0.69

31
32
33
34
35

HLA-A*33:01
HLA-A*68:01
HLA-A*31:01
HLA-A*23:01
HLA-A*24:02

306
306
310
312
312

319
319
319
320
320

FTVEKGIYQTSNFR
FTVEKGIYQTSNFR
KGIYQTSNFR
IYQTSNFRV
IYQTSNFRV

ann
ann
Consensus
Consensus
Consensus

0.72
0.37
0.28
0.68
0.34

36
37
38
39
40

HLA-A*03:01
HLA-A*30:02
HLA-B*15:01
HLA-A*02:01
HLA-A*32:01

408
408
408
417
417

417
421
421
425
425

RQIAPGQTGK
RQIAPGQTGKIADY
RQIAPGQTGKIADY
KIADYNYKL
KIADYNYKL

Consensus
ann
ann
Consensus
Consensus

0.63
0.61
0.3
0.7
0.5

41
42
43
44
45
46

HLA-A*01:01
HLA-A*30:02
HLA-A*31:01
HLA-A*33:01
HLA-A*24:02
HLA-A*33:01

440
441
441
442
443
444

453
453
454
454
456
457

NLDSKVGGNYNYLY
LDSKVGGNYNYLY
LDSKVGGNYNYLYR
DSKVGGNYNYLYR
SKVGGNYNYLYRLF
KVGGNYNYLYRLFR

ann
ann
ann
ann
ann
ann

0.08
0.31
0.47
0.67
0.46
0.16

47

HLA-A*33:01

455

466

LFRKSNLKPFER

ann

0.96

48
49
50
51
52
53

HLA-A*31:01
HLA-A*01:01
HLA-B*40:01
HLA-B*15:01
HLA-B*35:01
HLA-B*40:01

458
460
464
473
478
479

466
473
472
486
489
492

KSNLKPFER
NLKPFERDISTEIY
FERDISTEI
YQAGSTPCNGVEGF
TPCNGVEGFNCY
PCNGVEGFNCYFPL

Consensus
ann
Consensus
ann
ann
ann

0.14
0.63
0.88
0.97
0.81
0.31

54
55
56
57
58
59
60
61

HLA-A*23:01
HLA-A*24:02
HLA-A*24:02
HLA-B*35:01
HLA-B*53:01
HLA-B*15:01
HLA-A*68:02
HLA-A*01:01

488
488
488
490
490
492
495
499

497
497
501
497
497
505
503
508

CYFPLQSYGF
CYFPLQSYGF
CYFPLQSYGFQPTN
FPLQSYGF
FPLQSYGF
LQSYGFQPTNGVGY
YGFQPTNGV
PTNGVGYQPY

Consensus
Consensus
ann
Consensus
Consensus
ann
Consensus
Consensus

0.13
0.12
0.7
0.71
0.71
0.14
0.8
0.8

62
63

HLA-A*03:01
HLA-B*07:02

517
520

529
533

LLHAPATVCGPKK
APATVCGPKKSTNL

ann
ann

0.82
0.9

64
65

HLA-A*68:01
HLA-A*68:02

568
568

577
576

DIADTTDAVR
DIADTTDAV

Consensus
Consensus

0.34
0.7

66
67

HLA-A*01:01
HLA-A*30:02

599
603

612
612

TPGTNTSNQVAVLY
NTSNQVAVLY

ann
Consensus

0.55
0.79

68
69
70
71
72
73

HLA-B*53:01
HLA-B*57:01
HLA-B*58:01
HLA-B*35:01
HLA-B*53:01
HLA-A*24:02

620
622
622
625
625
630

633
633
635
636
633
643

VPVAIHADQLTPTW
VAIHADQLTPTW
VAIHADQLTPTWRV
HADQLTPTWRVY
HADQLTPTW
TPTWRVYSTGSNVF

ann
ann
ann
ann
Consensus
ann

0.21
0.47
0.27
0.54
0.2
0.51

74
75
76
77
78

HLA-A*31:01
HLA-A*23:01
HLA-B*15:01
HLA-A*68:01
HLA-A*02:06

633
634
634
637
643

646
643
643
646
651

WRVYSTGSNVFQTR
RVYSTGSNVF
RVYSTGSNVF
STGSNVFQTR
FQTRAGCLI

ann
Consensus
Consensus
Consensus
Consensus

0.29
0.62
0.21
0.96
0.64

79

HLA-A*30:02

651

660

IGAEHVNNSY

Consensus

0.35

80
81
82
83
84
85
86
87
88
89
90

HLA-A*30:01
HLA-A*30:02
HLA-A*31:01
HLA-A*33:01
HLA-A*33:01
HLA-B*07:02
HLA-B*07:02
HLA-B*07:02
HLA-B*08:01
HLA-B*57:01
HLA-B*58:01

683
683
673
673
677
676
679
680
680
685
685

691
695
682
682
685
689
692
692
688
697
693

RARSVASQS
RARSVASQSIIAY
SYQTQTNSPR
SYQTQTNSPR
QTNSPRRAR
TQTNSPRRARSVAS
NSPRRARSVASQSI
SPRRARSVASQSI
SPRRARSVA
RSVASQSIIAYTM
RSVASQSII

Consensus
ann
Consensus
Consensus
Consensus
ann
ann
ann
Consensus
ann
Consensus

0.5
0.46
0.64
0.7
0.55
0.7
0.09
0.04
0.72
0.7
0.4

91
92
93
94
95
96
97
98

HLA-A*23:01
HLA-A*32:01
HLA-A*68:02
HLA-B*15:01
HLA-B*35:01
HLA-B*44:02
HLA-B*44:02
HLA-B*44:03

705
704
703
699
699
700
701
701

718
712
712
707
707
712
714
714

VAYSNNSIAIPTNF
SVAYSNNSI
NSVAYSNNSI
LGAENSVAY
LGAENSVAY
GAENSVAYSNNSI
AENSVAYSNNSIAI
AENSVAYSNNSIAI

ann
Consensus
Consensus
Consensus
Consensus
ann
ann
ann

0.65
0.8
0.99
0.8
0.3
0.49
0.12
0.31

99

HLA-A*68:02

773

785

EQDKNTQEVFAQV

ann

0.71

100
101
102
103
104
105

HLA-A*02:06
HLA-A*03:01
HLA-A*30:01
HLA-A*32:01
HLA-B*15:01
HLA-A*03:01

786
786
786
786
786
787

794
795
795
794
797
795

KQIYKTPPI
KQIYKTPPIK
KQIYKTPPIK
KQIYKTPPI
KQIYKTPPIKDF
QIYKTPPIK

Consensus
Consensus
Consensus
Consensus
ann
Consensus

0.38
0.47
0.52
0.3
0.73
0.27

106
107

HLA-B*07:02
HLA-B*57:01

811
811

818
823

KPSKRSFI
KPSKRSFIEDLLF

Consensus
ann

0.95
0.65

108
109
110
111

HLA-A*03:01
HLA-A*11:01
HLA-A*68:01
HLA-A*01:01

1136
1136
1136
1142

1149
1149
1149
1155

TVYDPLQPELDSFK
TVYDPLQPELDSFK
TVYDPLQPELDSFK
QPELDSFKEELDKY

ann
ann
ann
ann

0.15
0.14
0.34
0.55

112
113

HLA-B*40:01
HLA-A*01:01

1257
1259

1265
1272

DEDDSEPVL
DDSEPVLKGVKLHY

Consensus
ann

0.86
0.64

Table 6. IEDB prediction of binding affinity with MHC-II alleles, only our selected peptides with percentile rank less than 1.00 are
shown here. The binding affinity is considered higher for low percentile rank. Sequences that match our selected peptides are marked
in red.
Sl. No.
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21

Allele

Start

End

Method

HLA-DPA1*01:03/DPB1*04:01
HLA-DPA1*02:01/DPB1*05:01
HLA-DPA1*02:01/DPB1*05:01
HLA-DQA1*05:01/DQB1*03:01
HLA-DQA1*05:01/DQB1*03:01
HLA-DRB1*04:01
HLA-DRB1*15:01
HLA-DRB3*01:01
HLA-DRB3*01:01
HLA-DRB1*11:01
HLA-DRB1*11:01
HLA-DRB3*01:01
HLA-DPA1*02:01/DPB1*01:01
HLA-DPA1*01:03/DPB1*02:01
HLA-DRB1*01:01
HLA-DRB1*01:01
HLA-DRB1*07:01
HLA-DQA1*04:01/DQB1*04:02
HLA-DQA1*03:01/DQB1*03:02
HLA-DPA1*01:03/DPB1*04:01
HLA-DRB1*13:02

168
183
184
255
255
314
319
400
402
443
444
461
501
501
514
515
684
763
764
809
1127

185
197
197
268
269
331
335
413
418
460
457
472
518
518
526
528
701
775
776
826
1141

NetMHCIIpan
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
Consensus
NetMHCIIpan
Consensus

Percentile
Rank
FEYVSQPFLMDLEGKQGN
0.87
QGNFKNLREFVFKNI
0.74
GNFKNLREFVFKNI
0.62
SSGWTAGAAAYYVG
0.76
SSGWTAGAAAYYVGY
0.94
QTSNFRVQPTESIVRFPN
1
RVQPTESIVRFPNITNL
0.95
FVIRGDEVRQIAPG
0.47
IRGDEVRQIAPGQTGKI
0.94
SKVGGNYNYLYRLFRKSN
0.65
KVGGNYNYLYRLFR
0.9
LKPFERDISTEI
0.79
NGVGYQPYRVVVLSFELL
0.38
NGVGYQPYRVVVLSFELL
0.6
SFELLHAPATVCG
0.02
FELLHAPATVCGPK
0.49
ARSVASQSIIAYTMSLGA
0.77
LNRALTGIAVEQD
0.73
NRALTGIAVEQDK
0.91
PSKPSKRSFIEDLLFNKV
0.59
DVVIGIVNNTVYDPL
0.7
Peptide

